iBio shares are trading higher after the company announced that a single dose of its IBIO-610 treatment lowered levels of metabolism regulat
iBio shares are trading higher after the company announced that a single dose of its IBIO-610 treatment lowered levels of metabolism regulator protein Activin E in primates for up to 8 weeks.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.